Company news
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) news
Every Arrowhead Pharmaceuticals, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases — page 6
Arrowhead Pharmaceuticals Reports Fiscal 2020 Second Quarter Results
May 7, 2020
Arrowhead Pharmaceuticals to Participate in Upcoming May 2020 Conferences
May 1, 2020
Arrowhead Pharmaceuticals Announces Retirement of COO Bruce Given
May 1, 2020
Arrowhead Pharmaceuticals to Webcast Fiscal 2020 Second Quarter Results
April 22, 2020
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1/2a Study of ARO-ENaC for Treatment of Cystic Fibrosis
April 10, 2020
Arrowhead Pharmaceuticals Announces Precautionary Measures to Mitigate Effects of Novel Coronavirus (COVID-19) Spread
March 17, 2020
Arrowhead Pharmaceuticals Initiates Phase 1/2 Study of ARO-HSD in Normal Healthy Volunteers and Patients with NASH or Suspected NASH
March 3, 2020
Arrowhead Pharmaceuticals to Participate in Upcoming March 2020 Conferences
March 2, 2020
Arrowhead Reports Interim Clinical Data on Cardiometabolic Candidates ARO-APOC3 and ARO-ANG3
February 5, 2020
Arrowhead Pharmaceuticals Reports Fiscal 2020 First Quarter Results
February 5, 2020
Arrowhead Pharmaceuticals to Webcast Fiscal 2020 First Quarter Results
January 22, 2020
Arrowhead Pharmaceuticals Appoints James Hassard as Chief Commercial Officer
January 6, 2020
Arrowhead Pharmaceuticals Doses First Patient in AROAAT2002 Open Label Phase 2 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease
December 20, 2019
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1 Study of ARO-HSD for Treatment of Alcohol and Nonalcohol Related Liver Disease
December 16, 2019
Arrowhead Pharmaceuticals Appoints Marianne De Backer to Board of Directors
December 13, 2019
Arrowhead Pharmaceuticals Files IND for Phase 1b Study of ARO-HIF2 for Treatment of Clear Cell Renal Cell Carcinoma
December 11, 2019
Arrowhead Pharmaceuticals Closes Underwritten Public Offering with Gross Proceeds of $266.8 Million
December 6, 2019
Arrowhead Pharmaceuticals Announces Pricing of Underwritten Public Offering of Common Stock
December 4, 2019
Arrowhead Pharmaceuticals Announces Proposed Underwritten Offering of Common Stock
December 2, 2019
Arrowhead Pharmaceuticals to Participate in Upcoming December 2019 Conferences
November 26, 2019
Arrowhead Pharmaceuticals Reports Fiscal Year 2019 Results
November 25, 2019
Arrowhead Presents New Clinical Data on Cardiometabolic Candidates ARO-APOC3 and ARO-ANG3 at AHA Scientific Sessions 2019
November 18, 2019
Arrowhead Pharmaceuticals Announces Planned Management Transition
November 15, 2019
Arrowhead Pharmaceuticals to Webcast Fiscal 2019 Year End Results
November 11, 2019
Arrowhead and Collaborator Janssen Present Phase 2 Clinical Data for Investigational Hepatitis B Regimens at The Liver Meeting® 2019
November 8, 2019
Arrowhead Pharmaceuticals Presents Preclinical Data on ARO-ENaC at the North American Cystic Fibrosis Conference
October 31, 2019
Arrowhead Pharmaceuticals Hosts R&D Day on Emerging Pipeline of RNAi Therapeutics
October 18, 2019
Arrowhead Pharmaceuticals to Host R&D Day on Emerging Pipeline of RNAi Therapeutics
October 2, 2019
Arrowhead Pharmaceuticals to Participate in Upcoming October 2019 Conferences
September 30, 2019
Arrowhead Pharmaceuticals Presents Initial Top-Line Clinical Data and Preclinical Data on RNAi Candidates ARO-APOC3 and ARO-ANG3
September 16, 2019